Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tacrolimus (FK506) P-III, Open-label Study in Severe Refractory Ulcerative Colitis Patients or Patients Who Attended and Received Placebo in F506-CL-1107 Study

NCT00643071 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00643071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00643071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tacrolimus (FK506) P-III, Open-label Study in Severe Refractory Ulcerative Colitis Patients or Patients Who Attended and Received Placebo in F506-CL-1107 Study
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2006
Completion date
May 31, 2008
Enrollment
32 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis